Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II rituximab dosing schedules in relapsed or refractory immune thrombocytopenic purpura
NL-OMON23430Phase 2Active, not recruiting
- Start
- Sep 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in immune thrombocytopenia (ITP) (3 arms). Primary endpoints: Overall response to treatment and Response rate threshold by arm. Started Sep 2005; status: active, not recruiting.
02
Drugs
rituximab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON23430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23430.